VCYT
Veracyte, Inc. (Russell 2000)
Healthcare — Diagnostics & Research
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Price History
Fundamentals
| Market Cap | $4.44B |
| P/E Ratio (TTM) | 51.53 |
| Forward P/E | 29.49 |
| EPS (TTM) | $1.08 |
| Dividend Yield | - |
| Profit Margin | 16.25% |
| Revenue Growth | 21.50% |
| ROE | 6.93% |
| Debt/Equity | 2.93 |
| Recommendation | Buy 1.7 |
| Analyst Target | $56.55 |
| Analysts | 11 |
| Indexes | Russell 2000 |
Technical Indicators
| RSI (14) | 48.7 |
| Beta | 1.93 |
| SMA 20 | $57.74 |
| SMA 40 | $54.64 |
| 52-Week High | $60.91 |
| 52-Week Low | $22.92 |
| 50-Day Avg | $52.18 |
| 200-Day Avg | $41.50 |
| Avg Volume | $1.24M |
| Volume | 740.2K |
Performance Analysis
BULLISHVCYT shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 28, 2026 21:01 UTC
Back to Screener Export Report